Table 7.

Association between genetic polymorphism and development of cervical cancer.

Type of polymorphism	Genotype	Cervical cancer, persons (%)	Control, persons (%)	Odds ratio (OR)	Confidence interval (CI), (95%)	χ2	p
GSTT1	+/+	12 (5.53)	57 (35.62)	0.11	0.05–0.21	67.15	0.00
	±	76 (35.02)	60 (37.50)	0.90	0.59–1.37
	−/−	129 (59.45)	43 (26.88)	3.99	2.56–6.21
GSTM1	+/+	108 (49.77)	116 (72.50)	0.38	0.24–0.58	25.31	<0.0001
	±	78 (35.94)	40 (25.00)	1.68	1.07–2.65
	−/−	31 (14.29)	4 (2.5)	6.5	2.25–18.81
XRCC1 Arg194Trp	Arg/Arg	163 (75.12)	105 (65.63)	1.58	1.01–2.48	8.72	0.01
	Arg/Trp	48 (22.12)	40 (25.00)	0.85	0.53–1.38
	Trp/Trp	6 (2.76)	15 (9.37)	0.27	0.10–0.73
XRCC1 Arg399Gln	Arg/Arg	78 (35.94)	66 (41.25)	0.80	0.53–1.22	7.24	0.03
	Arg/Gln	119 (54.84)	90 (56.25)	0.94	0.63–1.42
	Gln/Gln	20 (9.22)	4 (2.50)	3.96	1.33–11.82
XRCC3 Trp241Met	Trp/Trp	140 (64.51)	124 (77.50)	0.53	0.33–0.84	10.28	0.006
	Trp/Met	57 (26.27)	32 (20.00)	1.43	0.87–2.33
	Met/Met	20 (9.22)	4 (2.50)	3.96	1.33–11.82
TP53 Arg72Pro	Arg/Arg	85 (39.17)	49 (30.63)	1.46	0.95–2.25	5.15	0.08
	Arg/Pro	111 (51.15)	85 (53.12)	0.92	0.61–1.39
	Pro/Pro	21 (9.68)	26 (16.25)	0.55	0.30–1.02
CCND1 A870G	G/G	54 (25.12)	41 (25.62)	0.97	0.61–1.56	0.09	0.96
	G/A	103 (47.91)	78 (48.75)	0.97	0.64–1.46
	A/A	58 (26.97)	41 (25.63)	1.07	0.67–1.71